Does rapamycin extend human lifespan?
Weak EvidenceNO
Weak evidence exists for rapamycin extending human lifespan. While rapamycin consistently extends lifespan in animal models (mice, yeast, worms, flies) by inhibiting mTOR, human longevity data is nonexistent. Off-label use is growing but lacks clinical trial support for healthy aging.
The Verdict
Weak evidence exists for rapamycin extending human lifespan. While rapamycin consistently extends lifespan in animal models (mice, yeast, worms, flies) by inhibiting mTOR, human longevity data is nonexistent. Off-label use is growing but lacks clinical trial support for healthy aging.
What the Evidence Shows
Rapamycin (sirolimus) is an mTOR inhibitor originally developed as an immunosuppressant. Its longevity potential was discovered when the National Institute on Aging's Interventions Testing Program found it extended median lifespan in mice by 9-14%, even when started late in life. mTOR (mechanistic target of rapamycin) is a nutrient-sensing kinase that regulates cell growth, autophagy, and protein synthesis. Inhibiting mTOR mimics aspects of caloric restriction, upregulating autophagy and improving proteostasis. In animal models across multiple species, rapamycin is the most robustly replicated pharmacological lifespan intervention. However, translating these findings to humans faces major challenges. Rapamycin's immunosuppressive properties raise safety concerns for healthy individuals. A notable 2014 study by Mannick et al. showed low-dose mTOR inhibition (everolimus, a rapamycin analog) improved immune function in elderly humans, somewhat alleviating immunosuppression concerns at low doses. Despite this, no human clinical trials have measured lifespan or healthspan as primary endpoints. Current off-label use in the longevity medicine community typically involves intermittent low-dose protocols (5-6mg weekly) theorized to capture autophagy benefits while minimizing immunosuppression. This practice remains speculative and unsupported by rigorous evidence. The PEARL trial and other ongoing studies may eventually provide data, but results are years away.
Evidence Quality
1
Meta-Analyses
3
RCTs
4
Observational
Important Caveats
- ⚠️ No human clinical trials have measured lifespan as an endpoint
- ⚠️ Immunosuppressive effects pose safety risks for healthy individuals
- ⚠️ Optimal dosing for longevity versus transplant medicine is unknown
- ⚠️ Animal lifespan extensions may not translate to humans
- ⚠️ Off-label use is growing without adequate safety monitoring
Population Studied
Mouse models (C57BL/6, genetically heterogeneous); elderly humans aged 65+ in immune function trials; no healthy adult longevity trials
Dosage
Animal studies: 14 ppm in diet (mice); Human off-label use: 3-6mg weekly (intermittent); Mannick trial: 0.5mg daily everolimus equivalent
Duration
Mouse studies: lifelong treatment; Human immune function trials: 6-16 weeks; No long-term human aging trials completed
Supporting Studies (2)
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
RCTHarrison DE, Strong R, Sharp ZD, et al. · Nature (2009)
Rapamycin initiated at 600 days of age (approximately 60 human equivalent years) extended median lifespan by 9% in males and 14% in females across three independent sites in genetically heterogeneous mice.
View paper (DOI) →mTOR inhibition improves immune function in the elderly
RCTMannick JB, Del Giudice G, Sabatini M, et al. · Science Translational Medicine (2014)
Low-dose mTOR inhibition with everolimus for 6 weeks improved influenza vaccine response by approximately 20% in adults aged 65+, suggesting low-dose mTOR inhibition may enhance rather than suppress immune function in the elderly.
View paper (DOI) →Contradicting Studies (1)
Adverse effects of rapamycin: fact and folklore
ObservationalArriola Apelo SI, Lamming DW. · Future Medicinal Chemistry (2016)
Review of rapamycin side effects in transplant patients documented significant adverse effects including hyperlipidemia, impaired wound healing, mouth ulcers, and insulin resistance at therapeutic immunosuppressive doses, raising concerns about chronic use for longevity.
Why this disagrees:
Side effects observed at immunosuppressive doses may or may not apply to lower intermittent longevity doses, but without controlled trials at these lower doses, safety cannot be assumed. The therapeutic index for aging versus immunosuppression remains undefined.
Related Claims
Does caloric restriction extend human lifespan?
Weak EvidenceWeak evidence in humans: Caloric restriction dramatically extends lifespan in animals (worms, flies, mice), but human evidence is limited to biomarker improvements. No human study has proven lifespan extension.
Does metformin slow aging in non-diabetics?
Weak EvidenceWeak evidence supports metformin slowing aging in non-diabetics. Observational studies in diabetic populations show reduced all-cause mortality compared to non-diabetics, and animal data is supportive. However, no completed RCTs in healthy humans demonstrate anti-aging effects, and emerging evidence suggests it may blunt exercise adaptations.
Does NAD+ supplementation reverse aging?
Weak EvidenceWeak evidence for anti-aging effects in humans. NAD+ precursors (NMN, NR) reliably increase blood NAD+ levels, but no human trials have demonstrated reversal of aging biomarkers, functional improvements, or lifespan extension. Animal data is promising but translation remains unproven.